Two snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing
Fig 6
PLA2 activity of five venoms from Eswatini and their neutralisation by different antivenoms.
** indicates p < 0.01 by one-way ANOVA. A: PLA2 activity of B. arietans, D. polylepis, H. haemachatus, N. annulifera and N. mossambica. Data show the mean of three replicates and error bars represent standard deviation. Neutralisation of (B) H. haemachatus and (C) N. annulifera PLA2 activity by the three antivenoms SAIMR Polyvalent (SAVP), Panafrican (ICP) and PANAF (PS&V) at different doses, expressed as a percentage of a no antivenom control showing 100% activity. Data show the mean of three replicates and error bars represent standard deviation.